Patients
Patients will be recruited from the Antwerp University Hospital, Edegem, Belgium, by otolaryngologists at their tertiary tinnitus clinic. During this consult, patients will be thoroughly tested to exclude any objective causes of the tinnitus.
All patients will be assessed by means of medical history, ear-nose-throat (ENT) examination with micro-otoscopy, brain magnetic resonance imaging to exclude vascular compression or tumoral processes like acoustic neurinoma, audiometry (pure tone audiometry, tinnitus pitch and loudness matching and speech in noise test), tinnitus assessment comprising tinnitus loudness using a Visual Analogue Scale (VAS), tinnitus annoyance using the Tinnitus Questionnaire (TQ) and tinnitus severity using the Tinnitus Functional Index (TFI). Complementary, all the patients will undergo an electroencephalogram in which the auditory event-related potentials will be measured to investigate the alteration in processing of sound before and after TMJ treatment in an objective way [23].
Patients will be included when suffering from chronic somatic tinnitus, attributed to TMD or oral parafunctions, and which has been stable for at least 3 months. This diagnosis will be made by the ENT surgeon based on the abovementioned clinical process and using the diagnostic criteria for tinnitus attributed to TMD [24]. According to these criteria, tinnitus can be attributed to TMD or oral parafunctions when one of the following criteria are present, namely tinnitus association with manipulation of the teeth or jaw, temporal coincidence of onset or increase of both TMD pain and tinnitus, increase of tinnitus during inadequate postures when resting, walking, working or sleeping, or intense bruxism and/or clenching periods during the day or night (Table 1).
Table 1. Inclusion and exclusion criteria Additional evaluations in the context of this study involve temporomandibular assessment. During anamnesis, patients are questioned about the presence of bruxism and clenching. Furthermore, patients are screened on the presence of a painful TMD by the TMD pain screener [25]. In case a patient scores positive on at least three out of six questions of the TMD pain screener, the patient is suspected to suffer from a painful TMD (sensitivity 0.99 and specificity 0.95–0.98, respectively). The patient is then referred to the dentist, who will perform a clinical investigation according to the internationally recognised classification system for TMD [26].
Patients will be excluded in case of clear otological or neurological causes of the tinnitus such as Menière’s disease, severe depression (diagnosed by a psychiatrist), progressive middle ear pathology, intracranial pathology, traumatic cervical spine or temporomandibular injury in the past 6 months, tumours, previous surgery in the orofacial area, substance abuse that may affect the outcome measures or in case physical therapy treatment directed to the orofacial area is contra-indicated. Given the treatment that is studied, patients will also be excluded if they received TMD treatment in the past 2 months (Table 1).
Study design
This is a randomised controlled trial with a delayed treatment design (Fig. 1). At baseline, patients are randomly assigned by an independent researcher to the early-start group or to the delayed-start group. In part 1, the early-start group receives the TMD treatment for 9 weeks. The delayed-start group receives the standard information and advice about tinnitus, but no treatment in the first 9 weeks. In part 2, the patients in the delayed-start group receive TMJ treatment for the next 9 weeks. The early-start group now enters a follow-up period. In part 3, all patients enter a follow-up period. Follow-up data are collected after 18 and 27 weeks, in line with previous studies about somatic tinnitus of our research group [6, 27].
The results of the trial will be reported according to the CONSORT guidelines.
Randomisation procedure
Patients will be randomised into the early-start group or into the delayed-start group in a 1:1 ratio insuring an even distribution based on sex and age. The randomised list will be generated by an independent researcher using QMinim Online Minimisation® [28]. The assessor performing the clinical tests is blinded to the allocation of the patients in the direct-start or delayed-start group. This is possible because all patients are investigated 18 weeks after the start of their therapy (Fig. 1). The extra measurements in the delayed-start group, in week 18 of the study, are questionnaires that are completed via an online tool. Patients cannot be blinded in this protocol.
Outcome measures
Primary outcome measure
The primary outcome measure is change in tinnitus-related distress, measured using the Dutch version of the TQ, validated in 2007 [29, 30]. The TQ consists of 52 questions, of which 40 are used for calculating the total score and 2 are counted double (items 5 and 20). The questions are answered on a 3-point scale, ranging from ‘true’ (scoring 0) to ‘partly true’ (scoring 1) to ‘not true’ (scoring 2). The total score on the TQ ranges from 0 to 84. Higher scores correspond with higher tinnitus-related distress. The TQ shows high internal consistency (Cronbach’s alpha: 0.95) and a good correlation with the Tinnitus Handicap Inventory and Tinnitus Impairment Questionnaire (0.83–0.90) [31]. A decrease of 8.72 points is considered as clinically relevant (standardised response mean 1.04) [31].
Secondary outcome measures
Various secondary outcome measures will be measured and used to describe the population and identify possible mediating factors, i.e. factors that contribute to the therapeutic effect. An overview is presented in Table 2.
Table 2 Overview of primary and secondary outcome measures
Temporomandibular outcome measures
The TMD pain screener is a 6-item questionnaire regarding pain complaints from the orofacial region, and their dependency on functions, like opening wide or chewing. Internal consistency of the questionnaire is excellent, with coefficient α value of 0.93, reliability is acceptable (intraclass correlation coefficient 0.79), and it has excellent sensitivity and specificity (0.99 and 0.95–0.98, respectively) [25].
Apart from the questionnaire, a set of clinical TMD tests are performed to investigate the presence of a painful TMD. The examination includes the following tests:
-
The assessment of pain on active movements of the mandible, palpation of the jaw muscles and temporomandibular joint, and measuring of the mouth opening. This will be performed according to the standardised protocol of the Diagnostic Criteria/TMD [26]. Based on this examination, the presence of the specific TMD-pain diagnosis will be assessed as myalgia (sensitivity 0.90, specificity 0.99) and/or arthralgia (sensitivity 0.89, specificity 0.98).
-
Pressure pain thresholds (PPTs) will be measured using a hand-held algometer (Somedic AB, Farsta, Sweden). The PPTs will be measured on the temple, the masseter and the sternocleidomastoid muscles, and on the TMJ. The tibialis anterior muscle will be used as a reference point. The PPTs are expressed in kPa. The average of three measurements will be used for further calculations. For the measurement of PPTs, the pressure is progressively increased. Subjects have to report when the feeling of pressure changes into a feeling of pressure and pain by pressing a patient-controlled switch. Measuring pressure pain thresholds on masticatory muscles and the temporomandibular joint has been shown to be accurate and reliable [32].
Audiological outcome measures
The TFI [33] assesses tinnitus severity focusing on eight different domains, namely the unpleasantness of the tinnitus, reduced sense of control, cognitive interference, sleep disturbance, auditory difficulties attributed to the tinnitus, interference with relaxation, reduction in quality of life and emotional distress. The test-retest reliability of the TFI is good (r = 0.78). The convergent validity with the Tinnitus Handicap Inventory (r = 0.86) and VAS (r = 0.75) is good, as well as the discriminant validity with the Beck Depression Inventory-Primary Care (r = 0.56). A reduction of 13 points is considered to be clinically relevant. This questionnaire will be used to obtain a detailed view on the patients’ subjective tinnitus complaints.
The subjective loudness of the tinnitus is rated using a VAS. The patient is asked to indicate the average loudness of their tinnitus on a 10 cm horizontal line. On this line, the left end indicates ‘no tinnitus’ and the right end indicates ‘as loud as you can imagine’.
The Hospital Anxiety and Depression Scale (HADS) is a self-assessment scale developed to identify the possibility and probability of the presence of anxiety and depression among patients in non-psychiatric hospital clinics [34]. It consists of two subscales, an Anxiety subscale (HADS-A) and a Depression subscale (HADS-D), both containing seven intermingled items. All symptoms of anxiety or depression relating also to physical disorder, such as dizziness, headaches, insomnia, anergia and fatigue, are excluded to prevent intrusion from somatic disorders on the scores. Since symptoms relating to serious mental disorders were less common in patients attending a non-psychiatric hospital clinic, these symptoms are also excluded [34, 35]. The HADS has been found to be a reliable instrument for detecting states of depression and anxiety in the setting of a hospital medical outpatient clinic [34].
Hyperacusis is quantified and characterised using the Dutch version of the Hyperacusis Questionnaire (HQ) [36]. The HQ consists of 14 questions answered on a 4-point scale, ranging from ‘No’ (scoring 0 points), ‘Yes, a little’ (scoring 1 point), ‘Yes, quite a lot’ (scoring 2 points) to ‘Yes, a lot’ (scoring 3 points). Scores on the HQ consequently range from 0 to 42 and the cut-off value for hyperacusis is 28 points [37]. The HQ is used to investigate the presence of hyperacusis.
In addition to the questionnaires, a set of audiological parameters will be performed, comprising pure tone audiometry, tinnitus analysis and speech in noise test.
-
Pure tone audiometry, the key hearing test used to identify hearing threshold levels, will be measured according to the current clinical standards (ISO 8253-1, 1989), using a two-channel Interacoustics AC-40 audiometer in a soundproof booth. Air conduction thresholds will be measured at 125 Hz, 250 Hz, 500 Hz, 1 kHz, 2 kHz, 3 kHz, 4 kHz, 6 kHz and 8 kHz. This test is used to identify the presence and level of hearing loss. When the level of hearing loss corresponds to the tinnitus pitch, a causal relation can be expected [38].
-
The tinnitus analysis starts with identifying the type of tinnitus by asking whether one perceives a pulsatile or non-pulsatile tinnitus, whether the tinnitus is perceived constantly or not and whether the tinnitus sound is a pure tone, a noise or a mixture of different sounds (polyphonic); the tinnitus pitch is then assessed. The pitch is the psychoacoustic equivalent of the physical parameter frequency and is obtained by use of a pitch-matching technique that is the quantitative and qualitative description of the spectral characteristics of the tinnitus. For this technique, a two-alternative forced choice procedure is employed, using the contralateral ear as the reference ear. In cases where tinnitus is perceived bilaterally, the choice of ear is arbitrary. Using this technique, an attempt is made to identify the centre pitch of the tinnitus. When multiple tinnitus sounds are perceived, it is suggested to concentrate on the most troublesome tinnitus sound. Each time a pair of pure tones, or noises in case of noise-like tinnitus, differing by one or more octaves, are presented to the subject, who has to indicate which of the tones resembles the tinnitus the most. This procedure is repeated and finer adjustments are made to obtain the most exact match of tinnitus pitch possible. Afterwards, a tinnitus loudness matching is performed. Loudness is the perceptual correlate of the sound intensity. The tone (or noise) defined as the pitch match is presented to the ipsilateral ear when appropriate and a loudness match is made by use of an alternating procedure. Because of the compressed dynamic range frequently present at the tinnitus frequency, final loudness measurements are made with 1 dB steps. This measures the absolute level of tinnitus loudness expressed in dB hearing level. In addition, a calculation is made to provide a measurement of relative loudness expressed in dB sensation level, that is, the level of the loudness match minus the auditory threshold at tinnitus frequency. The tinnitus analysis provides an objective image of the perceived sound [38].
-
Speech in noise tests are performed to investigate whether or not patients with somatic tinnitus attributed to TMD, in whom no hearing loss is assumed, perform worse on speech in noise tests. The Leuven Intelligibility Sentence Test [39], a Dutch sentence test, will be applied; it consists of 35 lists of 10 sentences that are a reflection of daily communication and are of equivalent difficulty. An adaptive procedure is used with the noise at a fixed level of 65 dB sound pressure level. The procedure starts at a signal-to-noise ratio of 0 dB, meaning that speech and noise are presented equally loud (65 dB sound pressure level). Subsequently, the intensity level within a list of sentences is varied in steps of 2 dB adaptively in a one-down (when the keywords in the sentence are correctly repeated), one-up (when the keywords in the sentence are incorrectly repeated) procedure to determine the 50% correct identification point, which is called the speech reception threshold, expressed in dB signal-to-noise ratio. Before starting the actual procedure, one list will be performed as a training list for both left and right ear.
Additionally, all patients will undergo an electroencephalogram in which the auditory event-related potentials will be measured to investigate the alteration in processing of sound before and after TMJ treatment in an objective way [23]. This provides an objective outcome measure besides the subjective outcome measures.
Finally, the information from medical history taking by an ENT doctor, who is part of the standard tinnitus assessment, is used to gain insight into the duration of the complaints. Questions referring to the diagnostic criteria of somatic tinnitus are also included in the anamnesis, including duration of the complaints, localisation of the tinnitus (unilateral, bilateral or central), tinnitus association with some manipulation of the teeth or jaw, temporal coincidence of appearance or increase of both pain and tinnitus, increase of tinnitus during inadequate postures during rest, walking, working or sleeping, bruxism and/or clenching periods during day or night. In Table 2, an overview of the primary and secondary outcome measures is presented.
Intervention
TMD treatment is multifactorial, and is provided by dentists and physical therapists. It consists of patient education on normal jaw function, avoidance of overuse in oral ‘bad habits’ such as nail biting and tooth clenching. In case of grinding, night time use of stabilisation splints can be applied. Bothersome malocclusions will be addressed, e.g. by providing stabilisation splints. Patients are encouraged to relax their masticatory muscles, and relaxation of the muscles will be trained. Painful muscles will be stretched, wherein stretching techniques will be instructed to the patients so they can continue these exercises at home. During every physical therapy session, these exercises will be boosted to enhance patient compliance [40]. In total, the treatment period can last up to 9 weeks. This is longer than the traditional 6 weeks, yet it is based on our previous trial concerning cervicogenic somatic tinnitus, where an increase of complaints was observed after 6 weeks of therapy [6]. We therefore provide 3 additional weeks where the patient can be followed-up by the treating healthcare professional. Depending on the needs, up to 18 physical therapy sessions can be scheduled over a period of 9 weeks; two sessions per week for the first 3 weeks, one session per week for the next 6 weeks, and optional additional sessions to monitor patient compliance.
Trained clinicians will provide treatment. All participating clinicians are trained in the treatment protocol by the researchers. Patients with tinnitus attributed to a TMD will be referred to the trained clinicians for TMD treatment (guided referral).
Sample size and power
The primary outcome measure, the TQ, will be used to investigate differences between the direct-start group and delayed-start group in week 9 of the study. We plan to include patients in both groups in a 1:1 ratio. Based on literature data [31], we expect a minimal significant decrease in TQ score of 8.72 points (SD 13.72). To be able to reject the null hypothesis that the population means of the direct-start group and delayed-start group in week 9 are equal with probability (power) of 0.8, we will need to study 37 patients in each group. The Type I error probability associated with this test of this null hypothesis is 0.05.
This sample size will be refined after a pilot study containing 2 × 5 patients. Considering the possibility of dropouts and the later analysis of prognostic indicators and mediation analysis, we aim to recruit 2 × 100 patients.
The primary analysis population is the intention-to-treat population. This population includes all randomised patients who provided baseline data, regardless of whether or not they adhere to the complete protocol.
Statistics
Our null hypothesis is that the change in TQ at week 9 is equal in both groups (early-start and delayed-start):
H0: Change in TQ-baseline to TQ-9 weeks (early start) = Change in TQ-baseline to TQ-9 weeks (delayed start).
The primary outcome is a change in the scores on the TQ after 9 weeks of treatment. The mean change in TQ score between baseline and 9-week (post treatment) scores will be calculated. This mean change in TQ of the early start group will be compared to the mean change in TQ of the delayed-start group that has not yet received treatment at this point. A difference between both groups will be defined as statistically significant when p < 0.05.
A repeated measures ANOVA and post-hoc tests will be used to compare the mean changes of the early-start group and delayed-start group at 9 weeks, and secondary at baseline, 18, and 27 weeks follow-up. The same cut-off point of p < 0.05 will be used here.
For the mediation analysis, the protocol described by Baron and Kenny [41] will be used to calculate the role of potential contributing factors in the obtained output. This implies the execution of three regression analyses. The first will assess the relation between the applied therapy (independent variable) and the outcome (dependent variable). The second will assess the relation between the applied therapy (independent) and a mediating factor to confirm that the applied treatment significantly affects the mediator. The third will be used to confirm that the mediator significantly predicts the treatment outcome (dependent variable), while controlling for the applied treatment (independent variable). Again, a cut-off point of p < 0.05 will be used.
Bootstrapping will be performed to avoid overestimation of the mediation effect. As potential mediating factors, all secondary outcome measures will be used.